Toxicological investigation of lilial.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 10 2023
28 10 2023
Historique:
received:
08
08
2023
accepted:
21
10
2023
medline:
30
10
2023
pubmed:
29
10
2023
entrez:
29
10
2023
Statut:
epublish
Résumé
Lilial (also called lysmeral) is a fragrance ingredient presented in many everyday cosmetics and household products. The concentrations of lilial in the final products is rather low. Its maximum concentration in cosmetics was limited and recently, its use in cosmetics products was prohibited in the EU due to the classification as reproductive toxicant. Additionally, according to the European Chemicals Agency, it was under assessment as one of the potential endocrine disruptors, i.e. a substance that may alter the function of the endocrine system and, as a result, cause health problems. Its ability to act as an androgen receptor agonist and the estrogenic and androgenic activity of its metabolites, to the best of our knowledge, have not yet been tested. The aim of this work was to determine the intestinal absorption, cytotoxicity, nephrotoxicity, mutagenicity, activation of cellular stress-related signal pathways and, most importantly, to test the ability to disrupt the endocrine system of lilial and its Phase I metabolites. This was tested using set of in vitro assays including resazurin assay, the CHO/HPRT mutation assay, γH2AX biomarker-based genotoxicity assay, qPCR and in vitro reporter assays based on luminescence of luciferase for estrogen, androgen, NF-κB and NRF2 signalling pathway. It was determined that neither lilial nor its metabolites have a negative effect on cell viability in the concentration range from 1 nM to 100 µM. Using human cell lines HeLa9903 and MDA-kb2, it was verified that this substance did not have agonistic activity towards estrogen or androgen receptor, respectively. Lilial metabolites, generated by incubation with the rat liver S9 fraction, did not show the ability to bind to estrogen or androgen receptors. Neither lilial nor its metabolites showed a nephrotoxic effect on human renal tubular cells (RPTEC/TERT1 line) and at the same time they were unable to activate the NF-κB and NRF2 signalling pathway at a concentration of 50 µM (HEK 293/pGL4.32 or pGL4.37). Neither lilial nor its metabolites showed mutagenic activity in the HPRT gene mutation test in CHO-K1 cells, nor were they able to cause double-strand breaks in DNA (γH2AX biomarker) in CHO-K1 and HeLa cells. In our study, no negative effects of lilial or its in vitro metabolites were observed up to 100 µM using different in vitro tests.
Identifiants
pubmed: 37898679
doi: 10.1038/s41598-023-45598-y
pii: 10.1038/s41598-023-45598-y
pmc: PMC10613275
doi:
Substances chimiques
lilial
T7540GJV69
Hypoxanthine Phosphoribosyltransferase
EC 2.4.2.8
NF-kappa B
0
NF-E2-Related Factor 2
0
Estrogens
0
Androgens
0
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18536Informations de copyright
© 2023. The Author(s).
Références
Cell Death Differ. 2011 Dec;18(12):1889-903
pubmed: 21660047
Food Chem Toxicol. 2020 Jul 15;141 Suppl 1:111430
pubmed: 32461162
Int Immunopharmacol. 2002 Feb;2(2-3):201-11
pubmed: 11811925
Int J Toxicol. 2004 May-Jun;23(3):171-7
pubmed: 15204720
Arch Toxicol. 2020 Dec;94(12):4115-4129
pubmed: 33057782
Biochem Soc Trans. 2015 Aug;43(4):621-6
pubmed: 26551702
J Environ Public Health. 2012;2012:713696
pubmed: 22991565
Contact Dermatitis. 2011 Nov;65(5):266-75
pubmed: 21943251
Methods Mol Biol. 2017;1554:273-283
pubmed: 28185200
Reprod Biol Endocrinol. 2014 Nov 04;12:102
pubmed: 25371027
Toxicol Sci. 2010 Feb;113(2):284-92
pubmed: 19767620
Front Pharmacol. 2021 Oct 20;12:758468
pubmed: 34744736
Mutat Res. 1991 Feb;246(2):255-84
pubmed: 1996124
Mutat Res. 2011 Oct 1;715(1-2):25-31
pubmed: 21824484
Mutat Res. 1983 May;113(3-4):173-215
pubmed: 6341825
Toxicol Res (Camb). 2020 Apr 24;9(2):91-100
pubmed: 32440340
Front Immunol. 2017 Apr 21;8:405
pubmed: 28484449
Clin Chem. 2009 Apr;55(4):611-22
pubmed: 19246619
Food Chem Toxicol. 2018 May;115:228-243
pubmed: 29548853
J Appl Toxicol. 2009 Jul;29(5):422-34
pubmed: 19338011
Regul Toxicol Pharmacol. 2014 Feb;68(1):16-22
pubmed: 24239523
J Pharm Sci. 2001 Jun;90(6):749-84
pubmed: 11357178
AAPS J. 2011 Dec;13(4):615-31
pubmed: 21969220
Front Cell Dev Biol. 2022 Feb 02;9:809952
pubmed: 35186957
Mutat Res. 2010 Dec 21;703(2):174-9
pubmed: 20801231
Oncogene. 1999 Nov 22;18(49):6853-66
pubmed: 10602461
Toxicol Sci. 2009 Feb;107(2):451-60
pubmed: 19033392
Pharmacol Ther. 2016 Jan;157:84-104
pubmed: 26617217
Mutat Res. 1987 Oct;189(2):135-41
pubmed: 3657829
Ageing Res Rev. 2016 Dec;32:38-50
pubmed: 27333827
Chem Res Toxicol. 2007 Jul;20(7):1019-30
pubmed: 17555332
Int J Hyg Environ Health. 2020 Aug;229:113594
pubmed: 32763837
J Appl Toxicol. 2013 Nov;33(11):1337-52
pubmed: 23576290
J Pharm Sci. 2021 Apr;110(4):1601-1614
pubmed: 33545187
Curr Protoc Toxicol. 2001 May;Chapter 3:Unit3.3
pubmed: 20941701
Clin Nephrol. 2005 Jul;64(1):41-6
pubmed: 16047644
Int J Hyg Environ Health. 2017 Mar;220(2 Pt A):123-129
pubmed: 27633268
Toxicol In Vitro. 2013 Feb;27(1):339-48
pubmed: 22940465
Arch Toxicol. 2023 Jan;97(1):279-294
pubmed: 36173422
Alcohol Health Res World. 1998;22(3):153-64
pubmed: 15706790
Environ Mutagen. 1984;6(4):539-44
pubmed: 6432525
J Neurosci Res. 2003 Dec 15;74(6):801-6
pubmed: 14648584
J Vis Exp. 2011 Mar 13;(49):
pubmed: 21445039
Toxins (Basel). 2023 Apr 01;15(4):
pubmed: 37104201
Toxins (Basel). 2020 Feb 28;12(3):
pubmed: 32121188
Contact Dermatitis. 2022 Jul;87(1):13-19
pubmed: 35165896